Further Accelerating Cell Line Development and Reducing CMC Timeline to 3 Months from DNA to IND: the Journey from COVID to Non-COVID Programs
Since the COVID-19 outbreak, unconventional cell line development (CLD) strategies have been employed to enable development of SARS-CoV-2-neutralizing antibodies at expedited speed. In this work, we summarize the accelerated development of a total of seven antibody programs, some of which have received emergency use authorization (EUA) approval in less than two years.
This scientific poster was originally presented during the 2023 ECI Cell Culture Engineering in Cancun, Mexico